Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| PLVAP | Q9BX97 | Plasmalemma vesicle-associated protein (Fenestrated endothelial-linked structure protein) (Plasmalemma vesicle protein 1) (PV-1) | Disease related genesHuman disease related genesPlasma proteins | 1 | Fusion and delivery mediationImmune mediationReceptor-signaling mediation | 8 | 0.50 | |||
| SASH3 | O75995 | SAM and SH3 domain-containing protein 3 (SH3 protein expressed in lymphocytes homolog) | Disease related genesPredicted intracellular proteins | Adhesion and uptake mediationImmune mediation | 8 | 0.50 | ||||
| TN13B | Q9Y275 | Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved into: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form] | Cancer-related genesCD markersFDA approved drug targets | 1 | Lupus erythematosusLymphomaMultiple myeloma | Adhesion and uptake mediationClinical-translation mediationImmune mediation | 8 | 0.50 | ||
| ANK3 | Q12955 | Ankyrin-3 (ANK-3) (Ankyrin-G) | Cancer-related genesDisease related genesHuman disease related genes | Adhesion and uptake mediationFusion and delivery mediationMetabolism mediation | 7 | 0.50 | ||||
| APOD | P05090 | Apolipoprotein D (Apo-D) (ApoD) | Cancer-related genesCandidate cardiovascular disease genesPlasma proteins | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 7 | 0.50 | ||||
| EI2BB | P49770 | Translation initiation factor eIF2B subunit beta (S20I15) (S20III15) (eIF2B GDP-GTP exchange factor subunit beta) | Disease related genesEssential proteinsHuman disease related genes | Immune mediationMetabolism mediation | 7 | 0.50 | ||||
| FAD1 | Q8NFF5 | Bifunctional FAD diphosphatase/FAD synthase [Includes: FAD diphosphatase (EC 3.6.1.18) (EC 3.6.1.22) (FAD pyrophosphatase) (FADPPase) (FADHy) (NADH diphosphatase); FAD synthase (FADSy) (EC 2.7.7.2) (FMN adenylyltransferase) (FMNAT) (Flavin adenine dinucleotide synthase)] | Disease related genesEnzymesHuman disease related genes | Metabolism mediation | 7 | 0.50 | ||||
| BICD2 | Q8TD16 | Protein bicaudal D homolog 2 (Bic-D 2) | Disease related genesHuman disease related genesPredicted intracellular proteins | Fusion and delivery mediation | 6 | 0.50 | ||||
| CNNM4 | Q6P4Q7 | Metal transporter CNNM4 (Ancient conserved domain-containing protein 4) (Cyclin-M4) | Disease related genesHuman disease related genesPotential drug targets | 3 | Fusion and delivery mediationMetabolism mediation | 6 | 0.50 | |||
| FBW1B | Q9UKB1 | F-box/WD repeat-containing protein 11 (F-box and WD repeats protein beta-TrCP2) (F-box/WD repeat-containing protein 1B) (Homologous to Slimb protein) (HOS) | Disease related genesHuman disease related genesPlasma proteins | Immune mediationMetabolism mediationReceptor-signaling mediation | 6 | 0.50 | ||||
| FBX38 | Q6PIJ6 | F-box only protein 38 | Disease related genesHuman disease related genesPredicted intracellular proteins | Adhesion and uptake mediationImmune mediation | 6 | 0.50 | ||||
| LITAF | Q99732 | Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LPS-induced TNF-alpha factor) (Small integral membrane protein of lysosome/late endosome) (p53-induced gene 7 protein) | Disease related genesHuman disease related genesPredicted intracellular proteins | Fusion and delivery mediationImmune mediationReceptor-signaling mediation | 6 | 0.50 | ||||
| TUB | P50607 | Tubby protein homolog | Disease related genesPredicted intracellular proteins | Bladder cancerBrain cancerBreast cancer | Clinical-translation mediationImmune mediationReceptor-signaling mediation | 6 | 0.50 | |||
| ANXA2 | P07355 | Annexin A2 (Annexin II) (Annexin-2) (Calpactin I heavy chain) (Calpactin-1 heavy chain) (Chromobindin-8) (Lipocortin II) (Placental anticoagulant protein IV) (PAP-IV) (Protein I) (p36) | Cancer-related genesDisease related genesFDA approved drug targets | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | ||||
| CD4 | P01730 | T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4) | CD markersDisease related genesFDA approved drug targets | 1 | Acute myeloid leukaemiaAsthmaHuman immunodeficiency virus disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | ||
| CD86 | P42081 | T-lymphocyte activation antigen CD86 (Activation B7-2 antigen) (B70) (BU63) (CTLA-4 counter-receptor B7.2) (FUN-1) (CD antigen CD86) | CD markersFDA approved drug targetsPredicted intracellular proteins | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | |||
| COG3 | Q96JB2 | Conserved oligomeric Golgi complex subunit 3 (COG complex subunit 3) (Component of oligomeric Golgi complex 3) (Vesicle-docking protein SEC34 homolog) (p94) | Essential proteinsPredicted intracellular proteins | Fusion and delivery mediationMetabolism mediation | 5 | 0.50 | ||||
| DYSF | O75923 | Dysferlin (Dystrophy-associated fer-1-like protein) (Fer-1-like protein 1) | Disease related genesHuman disease related genesPotential drug targets | 1 | Muscular dystrophy | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.50 | ||
| FZD6 | O60353 | Frizzled-6 (Fz-6) (hFz6) | Disease related genesG-protein coupled receptorsHuman disease related genes | 7 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.50 | |||
| KCJ15 | Q99712 | ATP-sensitive inward rectifier potassium channel 15 (Inward rectifier K(+) channel Kir1.3) (Inward rectifier K(+) channel Kir4.2) (Potassium channel, inwardly rectifying subfamily J member 15) | FDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins | 2 | Clinical-translation mediationFusion and delivery mediation | 5 | 0.50 | |||
| KCNN3 | Q9UGI6 | Small conductance calcium-activated potassium channel protein 3 (SK3) (SKCa 3) (SKCa3) (KCa2.3) | Disease related genesFDA approved drug targetsHuman disease related genes | 6 | Myelopathy | Clinical-translation mediationFusion and delivery mediation | 5 | 0.50 | ||
| KPTN | Q9Y664 | KICSTOR complex protein kaptin (Actin-associated protein 2E4) | Disease related genesHuman disease related genesPredicted intracellular proteins | Fusion and delivery mediation | 5 | 0.50 | ||||
| NKG2D | P26718 | NKG2-D type II integral membrane protein (Killer cell lectin-like receptor subfamily K member 1) (NK cell receptor D) (NKG2-D-activating NK receptor) (CD antigen CD314) | Cancer-related genesCD markersPredicted membrane proteins | 1 | Acute myeloid leukaemiaColorectal cancerCrohn disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | ||
| PK3CG | P48736 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PI3Kgamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-3-kinase subunit p110-gamma) (p110gamma) (Phosphoinositide-3-kinase catalytic gamma polypeptide) (Serine/threonine protein kinase PIK3CG) (EC 2.7.11.1) (p120-PI3K) | Cancer-related genesDisease related genesEnzymes | COVID-19Follicular lymphomaAdrenal cancer | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.50 | |||
| PRRT2 | Q7Z6L0 | Proline-rich transmembrane protein 2 (Dispanin subfamily B member 3) (DSPB3) | Disease related genesHuman disease related genesPotential drug targets | 1 | Fusion and delivery mediationReceptor-signaling mediation | 5 | 0.50 |